Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Sanson

Showing results (71-80 of 290) with videos related to

Pageof 29
Sort By:
International Journal of Molecular Sciences|October 13, 2021
Heterogeneity of Response to Iron-Based Metallodrugs in Glioblastoma Is Associated with Differences in Chemical Structures and Driven by FAS Expression Dynamics and Transcriptomic SubtypesAnne Vessières, Emie Quissac, Nolwenn Lemaire, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|January 13, 2022
Expression and Prognostic Value of CD80 and CD86 in the Tumor Microenvironment of Newly Diagnosed GlioblastomaMohammed H Ahmed, Isaias Hernández-Verdin, Franck Bielle, et al.
Journal of Neuro-Oncology|November 19, 2013
Molecular analysis of diffuse intrinsic brainstem gliomas in adultsGerman Reyes-Botero, Marine Giry, Karima Mokhtari, et al.
Human Mutation|October 2, 2010
COLD PCR HRM: a highly sensitive detection method for IDH1 mutationsBlandine Boisselier, Yannick Marie, Marianne Labussière, et al.
Neurology|October 5, 2012
Detection of IDH1 mutation in the plasma of patients with gliomaBlandine Boisselier, Jaime Gállego Pérez-Larraya, Marta Rossetto, et al.
Journal of Neuro-Oncology|April 7, 2007
FABP7 expression in glioblastomas: relation to prognosis, invasion and EGFR statusGentian Kaloshi, Karima Mokhtari, Catherine Carpentier, et al.
The Oncologist|November 24, 2025
Advances in the management of patients with IDH-mutant gliomaJessica Rossi, Alberto Picca, Orazio Santo Santonocito, et al.
Radiology|September 5, 2023
Neurochemical Differences between 1p/19q Codeleted and Noncodeleted IDH-mutant Gliomas by in Vivo MR SpectroscopyFrancesca Branzoli, Roberto Liserre, Dinesh K Deelchand, et al.
Journal of Neuro-Oncology|January 15, 2014
Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patientsVéronique Quillien, Audrey Lavenu, Marc Sanson, et al.
Neuro-Oncology|October 26, 2012
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practiceMichael Weller, Roger Stupp, Monika E Hegi, et al.
Pageof 29

Showing results (71-80 of 290) with videos related to

Sort By:
Pageof 29
International Journal of Molecular Sciences|October 13, 2021
Heterogeneity of Response to Iron-Based Metallodrugs in Glioblastoma Is Associated with Differences in Chemical Structures and Driven by FAS Expression Dynamics and Transcriptomic SubtypesAnne Vessières, Emie Quissac, Nolwenn Lemaire, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|January 13, 2022
Expression and Prognostic Value of CD80 and CD86 in the Tumor Microenvironment of Newly Diagnosed GlioblastomaMohammed H Ahmed, Isaias Hernández-Verdin, Franck Bielle, et al.
Journal of Neuro-Oncology|November 19, 2013
Molecular analysis of diffuse intrinsic brainstem gliomas in adultsGerman Reyes-Botero, Marine Giry, Karima Mokhtari, et al.
Human Mutation|October 2, 2010
COLD PCR HRM: a highly sensitive detection method for IDH1 mutationsBlandine Boisselier, Yannick Marie, Marianne Labussière, et al.
Neurology|October 5, 2012
Detection of IDH1 mutation in the plasma of patients with gliomaBlandine Boisselier, Jaime Gállego Pérez-Larraya, Marta Rossetto, et al.
Journal of Neuro-Oncology|April 7, 2007
FABP7 expression in glioblastomas: relation to prognosis, invasion and EGFR statusGentian Kaloshi, Karima Mokhtari, Catherine Carpentier, et al.
The Oncologist|November 24, 2025
Advances in the management of patients with IDH-mutant gliomaJessica Rossi, Alberto Picca, Orazio Santo Santonocito, et al.
Radiology|September 5, 2023
Neurochemical Differences between 1p/19q Codeleted and Noncodeleted IDH-mutant Gliomas by in Vivo MR SpectroscopyFrancesca Branzoli, Roberto Liserre, Dinesh K Deelchand, et al.
Journal of Neuro-Oncology|January 15, 2014
Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patientsVéronique Quillien, Audrey Lavenu, Marc Sanson, et al.
Neuro-Oncology|October 26, 2012
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practiceMichael Weller, Roger Stupp, Monika E Hegi, et al.
Pageof 29